Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 3393 


 
Table of Contents   
LETTER TO EDITOR  
Year : 2013  |  Volume : 19  |  Issue : 5  |  Page : 240-241
Helicobacter pylori in the era of probiotics: A controversial application


1 Department of Medical Microbiology, Utrecht University, Utrecht, Netherlands
2 Department of Bacteriology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3 Department of Biology, Kharazmi University, Karaj, Iran

Click here for correspondence address and email

Date of Web Publication13-Sep-2013
 

How to cite this article:
Abadi AT, Mobarez AM, Tabrizi FH. Helicobacter pylori in the era of probiotics: A controversial application. Saudi J Gastroenterol 2013;19:240-1

How to cite this URL:
Abadi AT, Mobarez AM, Tabrizi FH. Helicobacter pylori in the era of probiotics: A controversial application. Saudi J Gastroenterol [serial online] 2013 [cited 2020 Jan 28];19:240-1. Available from: http://www.saudijgastro.com/text.asp?2013/19/5/240/118140


Sir,

Owing to the increased rate of resistance among the Helicobacter pylori strains, the efficacy of the prescribed antibiotics has reduced globally. [1] Consequently, alternative approaches can be an option to overcome this unsolved issue in clinical trials. [2] Probiotics, as a living bacterium in gastrointestinal routes, which provides health benefits has been called as a potential candidate. Recently, several studies investigated the efficacy of different probiotics in experimental and large scale levels. Recently, Dajani et al., proposed Bifidobacterium infantis as a preferable adjuvant for several therapeutic regimens used to eradicate the H. pylori infection. [3] Although probiotic therapy as an adjuvant had been reported to be an effective approach for treatment of H. pylori, the exact mechanism is not clearly elucidated yet. Moreover, the success of each of the three investigated therapeutic regimens in study by Dajani et al., need to be evaluated separately. [2] In other words, prescription of probiotic (B. infantis) in H. pylori therapeutic regimens should be compared with particular negative control group. In other words, adding a probiotic (B. infantis) should be recommended under assumption of independent factors, including various treatment regimens. Altogether, the current findings should be recommended to clinicians with caution. Meanwhile, the current data by Dajani et al., can be a good pilot, which will be encouraging for other groups in the aforementioned area to disclose further interesting findings for drawing a comprehensive conclusion.

 
   References Top

1.Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter 2010;15:505-9.  Back to cited text no. 1
[PUBMED]    
2.Baryshnikova NV. Helicobacter pylori-associated gastroenterological diseases: Genetic features and probiotic treatment. Benef Microbes 2012;3:157-61.  Back to cited text no. 2
[PUBMED]    
3.Dajani AI, Abu Hammour AM, Yang DH, Chung PC, Nounou MA, Yuan KY, et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? Saudi J Gastroenterol 2013;19:113-20.  Back to cited text no. 3
[PUBMED]  Medknow Journal  

Top
Correspondence Address:
Amin T.B Abadi
Department of Medical Microbiology, Utrecht University, Utrecht
Netherlands
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1319-3767.118140

Rights and Permissions




 

Top
  
 
  Search
 
  
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed1199    
    Printed18    
    Emailed0    
    PDF Downloaded324    
    Comments [Add]    

Recommend this journal